Singapore, Aug. 7 -- Excellos, Lonza, and Akadeum Life Sciences have announced a new project aimed at redefining standards for cell therapy manufacturing by elevating the role of starting material quality.

This project brings together leaders in donor cell characterisation, automated manufacturing, and cell separation technology to explore how aligned, modular innovation can streamline workflows and improve outcomes across the cell and gene therapy (CGT) landscape.

Together, the companies are working to spotlight the value of flexible, integrated platforms-from donor sourcing through manufacturing. The project is intended to emphasise how upstream quality impacts downstream performance, and clinical consistency.

Excellosbrings its dono...